

ABX-PF1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Jessica H. Roark
Group Art Unit : 1644
Applicants : Hanson et al.
Application No. : 09/472,087 Conf. No. : 8298
Filed : December 23, 1999
Title : HUMAN MONOCLONAL ANTIBODIES TO
CTLA-4

MAILSTOP ISSUE FEE
Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

DECLARATION OF VAHE BEDIAN

I, Vahe Bedian, hereby declare that:

(1) I am a Research Advisor in the Immunology Department at Pfizer Inc. (herein-after "Pfizer"), Assignee of the above-identified application.

(2) Hybridoma cell lines PF1-4.1.1.1 and PF1-11.2.1.4 (herein-after "the subclones") referred to in the American Type Culture Collection (ATCC) deposit certificate attached to applicants' Amendment Under 37 C.F.R. § 1.312, filed concurrently herewith are identical to the hybridoma cell lines 4.1.1.1 and 11.2.1.4 specifically identified in the specification of the above application. The antibody

heavy and light chain cDNA sequences from subclones PF1-4.1.1.1 and PF1-11.2.1.4 were sequenced and compared to those of parent clones 4.1.1 and 11.2.1, respectively, which are disclosed in the figures of the above application. The cDNA sequence encoding the heavy chain (without the signal peptide sequence) from hybridoma cell line PF1-4.1.1.1 is identical to the corresponding sequence in SEQ ID NO: 53. The cDNA sequence encoding the light chain (without the signal peptide sequence) from hybridoma cell line PF1-4.1.1.1 is identical to the corresponding sequence in SEQ ID NO: 56. The cDNA sequence encoding the heavy chain (without the signal peptide sequence) from hybridoma cell line PF1-11.2.1.4 is identical to the corresponding sequence in SEQ ID NO: 61. The cDNA sequence encoding the light chain (without the signal peptide sequence) from hybridoma cell line PF1-11.2.1.4 is identical to the corresponding sequence in SEQ ID NO: 62.

(3) The subclones were froze and stored at the Bioprocess department at Pfizer according to Pfizer's usual business practice. Dr. Douglas C. Hansen, a named inventor in the above application, retrieved the subclones from the stored supply on April 15, 2003 and provided them to me. Under my supervision, the subclones were expanded and deposited at the ATCC on April 29, 2003.

Best Available Copy

(4) I hereby declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine, or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements may jeopardize the validity of a patent issuing from the above-identified application.

Date: July 3, 2003

Vahe Badian
Vahe Badian